MedTrace Logo

House Dust Mite Allergy Trial In Children

NCT04145219 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1460

Last updated 2024-06-12

Study results available
· View outcomes & findings →

Summary

A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)

Conditions

  • Allergic Rhinitis Due to Dermatophagoides Farinae
  • Allergic Rhinitis Due to Dermatophagoides Pteronyssinus
  • Allergic Rhinitis Due to House Dust Mite

Interventions

BIOLOGICAL

Sublingual allergy immunotherapy tablet

For daily administration (1 tablet per day)

OTHER

Placebo

For daily administration (1 tablet per day)

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Antje Schuster, MD · Professor of Pediatrics, Düsseldorf University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-12
Primary Completion
2023-04-01
Completion
2023-04-21
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Canada
  • France
  • Germany
  • Lithuania
  • Poland
  • Russia
  • Slovakia
  • Spain
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04145219 on ClinicalTrials.gov